Phase I/II Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer

Inclusion Criteria: * Histological confirmation of NSCLC is required before treatment (however, patients with a smoking history and radiographic findings suggestive of NSCLC may consent prior to biopsy to combine research and diagnostic procedures. * Age ≥ 18 years. * ECOG performance status 0-1 * Determined to be a surgical candidate for tumor resection by a multidisciplinary team. * Women of childbearing potential and men must use approved contraception during the study and for 4 months post-treatment. Pregnancy or suspected pregnancy must be reported immediately. * Adequate organ and marrow function. * Pre-treatment biopsies are mandatory, and tumors must be T1b or larger (\>1cm) and amenable to biopsy as determined by a multidisciplinary team. * Patients must consent to provide blood at designated study time points. * Patients must consent to core needle biopsies (at least 3 samples, as deemed safe by the performing surgeon/radiologist) prior to treatment initiation Exclusion Criteria: * History of autoimmune disorders or use of immunomodulatory drugs (including dupilumab) within 2 months prior to treatment initiation. * Active autoimmune disease requiring systemic treatment in the past year, excluding replacement therapies like thyroxine or insulin. * Use of immunosuppressive drugs or systemic steroids within 7 days prior to treatment, except chronic steroids ≤10mg prednisone or equivalent. * No smoking history or confirmed tissue or ctDNA evidence of actionable driver alterations (e.g. EGFR mutation, ALK, or ROS1 rearrangements) * Prior chemotherapy or radiotherapy for another primary tumor, or prior locoregional therapy to the target lesion. Therapy for a different cancer is acceptable. * Metastatic disease where surgery would not have curative intent. * Uncontrolled illness, including active infections requiring antibiotics, symptomatic heart failure, unstable angina, or psychiatric/social conditions impeding study compliance. * Pregnancy or nursing, due to potential harm to the fetus or infant. * Progressive malignancy requiring active treatment, except for certain stable cancers treated with curative intent * HIV infection with detectable viral load or not on a stable HAART regimen * Active Hepatitis B or C (PCR-detectable) * History of allogeneic hematopoietic or solid organ transplantation. * Documented hypersensitivity to protein therapeutics. * Any condition, therapy, or abnormality that may interfere with trial results, patient participation, or their best interest as per the investigator's judgment.